<DOC>
	<DOCNO>NCT00003391</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase I trial study effectiveness muJ591 monoclonal antibody treat patient metastatic prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Prostate Cancer That Has Not Responded Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : I . Define toxicity maximum tolerate dose monoclonal antibody muJ591 patient hormone independent prostate cancer . II . Define pharmacokinetics biodistribution monoclonal antibody muJ591 patient . III . Define human antimouse antibody response therapy . IV . Define preliminary efficacy therapy patient . OUTLINE : This dose escalation study . Patients receive single dose intravenous iodine I 131-labeled monoclonal antibody muJ591 day 0 , combine unlabeled ( cold ) dose monoclonal antibody muJ591 . Anterior posterior imaging obtain 1 hour label muJ591 administration day 0 , 2 , 4 , 6 . Subsequent cohort 3-6 patient receive fix iodine-labeled dos escalate cold dos monoclonal antibody muJ591 maximum tolerate dose reach . Patients follow minimum 8 week muJ591 therapy disease progression . Patients stable respond disease human anti-mouse antibody negative may receive subsequent treatment discretion principal investigator . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic adenocarcinoma prostate , define : Abnormal CT , MRI , bone scan and/or Rising prostate specific antigen ( PSA ) level ( 3 consecutive occasion least 6 week ) despite hormonal therapy PSA least 2.0 study entry No active CNS metastases PATIENT CHARACTERISTICS : Age : 21 Performance status : Karnofsky 60100 % Life expectancy : At least 6 month Hematopoietic : WBC great 3,500/mm3 Platelet count great 100,000/mm3 No serious hematologic disease Hepatic : SGOT le 2.0 time upper limit normal Bilirubin le 1.5 mg/dL No serious hepatic disease Renal : Creatinine le 2.0 mg/dL Calcium le 13.5 mg/dL No serious renal disease Cardiovascular : No active angina No New York Heart Association class IIIIV No serious cardiac disease Pulmonary : No serious respiratory disease Other : No active uncontrolled infection Evidence preexisting antimouse antibody time screen PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 6 week since prior cytotoxic chemotherapy Endocrine therapy : At least 6 week since prior adrenal hormone inhibitor corticosteroid therapy Antiandrogen therapy must discontinue prior measure PSA value Luteinizing hormonereleasing hormone analog must maintain study OR must discontinue least 10 week prior study entry ( 28 day depot preparation ) 24 week prior study entry ( 3 month depot preparation ) Radiotherapy : At least 6 week since prior radiotherapy Surgery : Not specify</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>